Jutia Group | What's Behind AbbVie's Rocking Q3 Earnings DailyFinance AbbVie's partnership with Biogen Idec on daclizumab also looks promising. The drug targets treatment of patients with relapsed or remitting multiple sclerosis. Daclizumab is currently in a late-stage study. AbbVie and Biogen expect that study to wrap ... AbbVie Inc (ABBV): AbbVie's CEO Discusses Q3 2013 Results - Earnings Call ... AbbVie Reports Third-Quarter 2013 Financial Results |
